Showing posts with label Tissue Engineered Skin Substitutes Market Industry. Show all posts
Showing posts with label Tissue Engineered Skin Substitutes Market Industry. Show all posts

Monday, 14 December 2015

Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Trends, and Forecast 2015 - 2023

Transparency Market Research has published a new report, titled “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023”. Based on the survey conducted, the report pegs the value of the global tissue engineered skin substitutes market at US$0.9 bn in 2014. The market, exhibiting an impressive CAGR of 17.20% between 2015 and 2023, is likely to reach US$3.8 bn by 2023.
Browse the full Tissue Engineered Skin Substitutes Market (by Type - Acellular, Cellular Allogeneic, Cellular Autologous, and Others; by Application - Burn Injury, Diabetic/Vascular Ulcer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023 report at http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html
Artificial skin substitutes or skin substitutes are derived from human tissue, synthetic materials, non-human tissue, or a combination of these materials. Tissue engineered skin substitutes are made up of cells, combination of matrices and cells, and extracellular matrix. In the past few years, the market for tissue engineered skin substitutes has been witnessing growth at a significant pace owing to the rise in the number of vascular ulcer and diabetes patients. Furthermore, as the geriatric population around the world increases, it is subsequently expected to boost the demand for tissue engineered skin substitutes.
The market, according to the report, has gained much demand due to the rise in medical tourism in the emerging economies of Asia. However, despite witnessing lucrative prospects worldwide, the risk of disease transmission and absence of favorable reimbursement policies in major economies could hamper the overall growth of the market during the period from 2015 to 2023, as per the information published in the report.
To provide a holistic overview, the report segments the global tissue engineered skin substitutes market into acellular, cellular autologous, cellular allogeneic, and others. Of these, the acellular skin segment held the largest share of the market in 2014 and is expected to rise at the highest CAGR between 2015 and 2023. The growth of this segment is mainly helped by the low cost and easy availability of these tissue engineered skin variants. Moreover, increasing preference for acellular skin substitutes than implant-based skin surgery is also likely to fuel demand from the global tissue engineered skin substitutes market, states the report. As per the American Society of Plastic Surgeons, more than 50% of plastic surgeons in the U.S. preferred using acellular matrix for skin surgeries in 2012. The growing demand from acellular skin substitutes, particularly from the developed nations, will therefore boost the global tissue engineered skin substitutes market.
In terms of application, the report segments the global market for tissue engineered skin substitutes into diabetic/vascular, burn injury, and others. Of these, the diabetic/vascular segment held the largest share in the market in 2014, and as per the report, the segment will rise at the highest CAGR during the forecast period.To present a comprehensive overview of the market, the report also profiles companies such as BSN medical, 3M Health Care, Mölnlycke Health, Medtronic, Integra LifeSciences Corporation, and Acelity, L.P., Inc.
The global tissue engineered skin substitutes market is segmented as follows:
Global Tissue Engineered Skin Substitutes Market, by Type
  • Acellular
  • Cellular Allogeneic
  • Cellular Autologous
  • Others
Global Tissue Engineered Skin Substitutes Market, by Application
  • Burn Injury
  • Diabetic/Vascular Ulcer
  • Others
Global Tissue Engineered Skin Substitutes Market, by Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • South Africa
    • Rest of MEA
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453

Tuesday, 27 October 2015

Global Tissue Engineered Skin Substitutes Market expected to reach USD 3.8 Billion in 2023

Tissue engineering is a sophisticated yet promising treatment option for the treatment of skin diseases and disorders. Tissue engineering entails the development of biological substitutes to restore damaged tissue or maintain tissue function via the use of both cellular and acellular materials. It thus calls for close collaboration between cell biologists, geneticists, clinicians, and other experts. With skin disorders and diseases on the rise, coupled with the booming medical tourism industry, the prospects of the tissue engineered skin substitutes market look promising.

The global tissue engineered skin substitutes market is on the brink of explosive growth over the next few years as more advances in the field are made. The fact that the tissue engineered skin substitutes market will grow at 17.2% CAGR between 2015 and 2023 also speaks volumes about the high degree of innovation that prevails in the market. According to Transparency Market Research, tissue engineered skin substitutes constituted a US$958.8 mn market. The market is expected to surge to US$3.8 bn by 2023. Acellular tissue engineered skin substitutes are more popular than cellular substitutes because of the comparatively attractive price that the former boast.
Use of Tissue Engineered Skin Substitutes was Highest for Diabetic Ulcers in 2014

The WHO predicting that diabetes will be the 7th leading cause of death by 2030 is indicative of the pandemic proportions this disease has attained. An alarming 25.0% of diabetics are diagnosed with diabetes-related ulcers, said the International Diabetes Federation in 2014. These ulcers can take months on end to heal even when great precautions are taken. In the case of acute 

For patients suffering from acute diabetic ulcers, skin substitutes are, in most cases, the only available option if they are to prevent their quality of life from being compromised. As a result of this, the demand for tissue engineered skin substitutes will continue to remain high from patients suffering from diabetic ulcers. 

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3854
Tissue Engineered Skin Substitutes Market Currently Concentrated in North America

The availability of a wide variety of tissue engineered skin substitutes is in itself the key factor responsible for keeping North America at the top of the global market. This wide choice of products on its part can be ascribed to the high prevalence of diabetes in North America. Besides diabetes, deep vein thrombosis (DVT) continues to impose an increasing burden on healthcare agencies in the U.S. The Centers for Disease Control and Prevention (CDC), in its report published in March 2015, says that about 900,000 people in the United States are diagnosed with DVT per year. Ulcers and lesions resulting from DVT are contributing to the demand for tissue engineered skin substitutes in North America. 

However, when it comes to lifestyle-related diseases, the Asia Pacific is inching closer to North America owing largely to the increasing affluence in countries in the former. Moreover, a sizeable aging population base in countries such as Japan, Singapore, and China put persons in this age group at a higher risk of diabetes and DVT. Thus, the investment potential of Asia Pacific will only continue to rise over the next few years. 

Browse Full Global Tissue Engineered Skin Substitutes Market Report With Complete TOC @ http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html
Contact us:
Mr. Nachiket
Transparency Market Research
90 State Street, 
Suite 700, 
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Tuesday, 15 September 2015

Global Tissue Engineered Skin Substitutes Market expected to reach USD 3.8 Billion in 2023

According to a new market research report published by Transparency Market Research “Tissue Engineered Skin Substitutes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023”, the global tissue engineered skin substitutes market was valued at USD 0.9 billion in 2014 and is estimated to reach USD 3.8 billion in 2023 expanding at a CAGR of 17.2% from 2015 to 2023.

Skin substitutes or artificial skin substitutes are derived from human tissue, non-human tissue, synthetic materials, and combination of the above materials. Tissue engineered skin substitutes are made up of cells, the extracellular matrix, and combination of cells and matrices. The tissue engineered skin substitutes market is growing at a significant pace due to rise in the number of diabetic and vascular ulcer patients, growing geriatric population, and increasing demand for minimally invasive surgical products. Moreover, growing medical tourism in regions such as Asia is likely to boost demand for tissue engineered skin substitutes. However, disease transmission and lack of favorable reimbursement could hamper market growth during the forecast period from 2015 to 2023. The global tissue engineered skin substitutes market was valued at USD 958.8 million in 2014 and is estimated to reach USD 3,873.5 million by 2023, expanding at a CAGR of 17.2% from 2015 to 2023.
Based on type, the global tissue engineered skin substitutes market has been segmented into acellular, cellular allogeneic, cellular autologous, and others. Acellular skin substitute was the largest segment of the tissue engineered skin substitutes market in 2014 and is projected to expand at the highest CAGR from 2015 to 2023. This growth is majorly due to easy availability, low cost, and high demand for these products. Moreover, growing preference for acellular skin substitutes for implant-based skin surgery is likely to contribute to the growth of the segment. For instance, the American Society of Plastic Surgeons (2012) stated that more than 50% surgeons in the U.S. preferred acellular matrix for skin surgeries. Hence, growing preference for acellular skin substitutes boosts demand for tissue engineered skin substitutes. However, high risk of post-implementation infection associated with allogeneic skin substitutes is expected to restrict market growth.
Based on application, the tissue engineered skin substitutes market has been segmented into burn injury, diabetic/vascular ulcer, and others. The diabetic and vascular ulcers segment held the largest share of the market in 2014 and is likely to expand at the highest CAGR during the forecast period due to rapid increase in the diabetic and vascular ulcer cases globally. For instance, according to International Diabetes Federation (2014), around 387 million people were diagnosed with diabetes across the world, and the number is expected to increase at a rapid pace. Skin substitutes are the ultimate choice for patients suffering from acute diabetic ulcers. Hence, escalating number of diabetic patients would fuel the growth of the tissue engineered skin substitutes market. However, lack of favorable reimbursement policies is expected to hamper market growth during the study period.

The global tissue engineered skin substitutes market is highly consolidated, with top four companies accounting for majority of the market share in 2014. Companies such as 3M Health Care, BSN medical, Medtronic, Acelity, L.P., Inc., Mölnlycke Health, and Integra LifeSciences Corporation are the key players operating in the global tissue engineered skin substitutes market.

Browse the full Tissue Engineered Skin Substitutes Market (by Type - Acellular, Cellular Allogeneic, Cellular Autologous, and Others; by Application - Burn Injury, Diabetic/Vascular Ulcer, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023 report at http://www.transparencymarketresearch.com/tissue-engineered-skin-substitute.html

The global tissue engineered skin substitutes market is segmented as follows:
Global Tissue Engineered Skin Substitutes Market, by Type
  • Acellular
  • Cellular Allogeneic
  • Cellular Autologous
  • Others
Global Tissue Engineered Skin Substitutes Market, by Application
  • Burn Injury
  • Diabetic/Vascular Ulcer
  • Others
Global Tissue Engineered Skin Substitutes Market, by Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • India
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • South Africa
    • Rest of MEA
About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.